Jiyue (Afatinib) 30mg/40mg Tablets | CTTQ China Generic | GLT

Generic Information: Jiyue (Afatinib) — CTTQ, China

Jiyue is a domestic Chinese generic of afatinib produced by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CTTQ), one of China's leading pharmaceutical groups. Supplied in compact 7-tablet strips in both 30 mg and 40 mg strengths, Jiyue offers a flexible, week-by-week format for patients with EGFR-mutant non-small cell lung cancer. CTTQ was among the first companies to gain afatinib generic approval in China, and Jiyue passed the national consistency evaluation, confirming its bioequivalence to the originator.

What Is Jiyue (Afatinib) Used For?

Jiyue is used to treat locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations, including exon 19 deletions, the L858R substitution, and uncommon mutations such as G719X, L861Q and S768I. It is a first-line therapy for EGFR-mutant NSCLC and is also used in metastatic squamous NSCLC after progression on platinum-based chemotherapy.

How Does Jiyue (Afatinib) Work?

Jiyue contains afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor that covalently binds EGFR, HER2 and ErbB4. This permanent blockade shuts down the signaling pathways that EGFR-mutant lung cancer cells depend on for growth and survival, delivering durable disease control and activity against uncommon EGFR mutations.

Indications

Jiyue is indicated for adults with locally advanced or metastatic non-small cell lung cancer whose tumors have non-resistant EGFR mutations, and for metastatic squamous NSCLC progressing after platinum-based therapy. EGFR mutation testing is required before starting treatment.

Dosage

The recommended dose is 40 mg once daily, taken at least one hour before or two hours after a meal. The 7-tablet strip represents one week of therapy, and the 30 mg strength is available for dose reduction or patients with severe renal impairment. Dose adjustments should be managed by the treating oncologist.

Side Effects

Common side effects of Jiyue include diarrhea, acneiform rash, stomatitis, paronychia, dry skin and decreased appetite. Serious adverse reactions such as interstitial lung disease, hepatotoxicity and severe skin disorders are uncommon but require prompt medical attention. Proactive management of diarrhea and skin symptoms supports adherence.

Storage

Store Jiyue in a cool, dry place away from sunlight and moisture, in its original packaging. Keep out of reach of children and swallow tablets whole with water.

Why Choose the GLT?

Jiyue through GLT brings a consistency-evaluated afatinib generic from CTTQ in a flexible weekly strip format, at a price that makes long-term EGFR-targeted therapy more affordable. As a Hong Kong-licensed supplier, we source genuine stock and provide the documentation needed for confident purchasing. For patients and institutions seeking a trusted domestic generic in both 30 mg and 40 mg strengths, Jiyue is an excellent choice.

How to Order Jiyue (Afatinib)

To order, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. Share your preferred strength, quantity and destination, and we will confirm availability and delivery.

FAQ

Who makes Jiyue? Jiyue is produced by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CTTQ), a leading Chinese pharmaceutical group.

What strengths are available? Jiyue is available in 30 mg and 40 mg strengths, both in 7-tablet strips.

Is Jiyue equivalent to the originator? Yes, Jiyue passed the national consistency evaluation, confirming bioequivalence to the originator afatinib.

Do I need a prescription? Yes, afatinib is a prescription oncology medicine used under physician supervision.